Bisphenol derivatives and their use as androgen receptor activity modulators

A compound having the following structure (I):

• or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein:
• X is —S(O)n— or —C(R8R9)—;
• R1 is H, hydroxyl or —OC(═O)R13;
• R2 is hydroxyl or —OC(═O)R13;
• R3 is halo, —OH, —OR4;
• —OC(═O)R13, —NH2, —NHC(═O)R13, —N(C(═O)R13)2, —NHS(O)nR5, —N(C(═O)R13)(S(O)nR5), —N(C1-C6 alkyl)(S(O)nR5), —S(O)nR5, —N3, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
• R4 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl, carbocyclyl, heteroaryl or heterocyclyl which are optionally substituted with one or more R6;
• R5 is each independently C1-C6 alkyl or aryl which are optionally substituted with one or more R6;
• R6 is each independently selected from the group consisting of H, F, Cl, Br, I, 123I, hydroxyl, oxo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 alkoxy, C6-C12 aryl, wherein each R6 is optionally substituted with one or more of halogen, 123I, 18F, hydroxyl, —OS(O)2-aryl, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
• R8 and R9 are each independently H or C1-C6 alkyl;
• R11a, R11b, R11c and R11d are each independently H, methyl, F, Cl, Br, I, or 123I;
• R13 is C1-C6 alkyl;
• and
• n is 0, 1, or 2;
• wherein at least one of R11a, R11b, R11c and R11d is methyl F, Cl, Br, I, or 123I.